Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505965 | 1.00 | CA1 (0.48) | CA1CA2KDM4ESMN1; SMN2 | |
| SCHEMBL4196637 | 0.83 | THRA (0.33) | CA1CA2KDM4ESMN1; SMN2 | |
| SCHEMBL4196635 | 0.83 | THRA (0.33) | CA1CA2KDM4ESMN1; SMN2 | |
| SCHEMBL11814265 | 0.83 | ALDH1A1 (0.33) | SMN1; SMN2 | |
| SCHEMBL2298579 | 0.82 | PRSS1 (0.45) | CA1CA2KDM4ESMN1; SMN2 | |
| SCHEMBL2298580 | 0.82 | PRSS1 (0.45) | CA1CA2KDM4ESMN1; SMN2 | |
| SCHEMBL8167757 | 0.80 | ALDH1A1 (0.48) | SMN1; SMN2 | |
| SCHEMBL10178590 | 0.80 | ALDH1A1 (0.48) | SMN1; SMN2 | |
| SCHEMBL12134413 | 0.80 | KDM4E (0.32) | KDM4ESMN1; SMN2 | |
| SCHEMBL506543 | 0.80 | CES2 (0.44) | KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751099-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9630956-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630956-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630956-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-25 | — | — | US | disclosed |
| EP-2694498-B1 | AMINOPYRAZINE COMPOUNDS USEFUL AS INHIBITORS OF TRA KINASE | VERTEX PHARMA (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2694498-B1 | AMINOPYRAZINE COMPOUNDS USEFUL AS INHIBITORS OF TRA KINASE | VERTEX PHARMA (US) | 2016-03-30 | — | — | EP | disclosed |
| US-8877759-B2 | Aminopyrazines as ATR kinase inhibitors | Vertex Pharnaceuticals Incorporated (US) | 2014-11-04 | — | — | US | disclosed |
| US-8853217-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| US-8846686-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2751099-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2012138938-A1 | AMINOPYRAZINE COMPOUNDS USEFUL AS INHIBITORS OF TRA KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012138938-A1 | AMINOPYRAZINE COMPOUNDS USEFUL AS INHIBITORS OF TRA KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-11 | — | — | WO | disclosed |
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011143426-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143426-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20090170911-A1 | NOVEL AZOLE COMPOUND | AJINOMOTO CO. INC (JP) | 2009-07-02 | — | — | US | disclosed |
| US-7517996-B2 | Azole compound | AJINOMOTO CO., INC. (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20060194850-A1 | Novel azole compound | AJINOMOTO CO. INC (JP) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170911-A1 | NOVEL AZOLE COMPOUND | LPAR1, LPAR2, LPAR3 | CA1 2436/4885CA2 1252/4885KDM4E 2822/4885 |
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | CA1 4196/4885CA2 2639/4885KDM4E 1834/4885 |
| US-20060194850-A1 | Novel azole compound | LPAR1, LPAR2, LPAR3 | CA1 2436/4885CA2 1252/4885KDM4E 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.